Frontiers in Cardiovascular Medicine

OCT 22, 2026 · JOURNAL ARTICLE

Cardiovascular health and longevity: where are we?

Frontiers in Cardiovascular Medicine

Cardiovascular health is a key factor in human longevity, affecting not just lifespan but also the quality of aging. We synthesize evidence across four risk factor domains: genetic

OCT 21, 2026 · JOURNAL ARTICLE

Integrated management of acute pulmonary embolism and the post-pulmonary embolism syndrome: risk stratification, modern therapies, and long-term follow-up

Frontiers in Cardiovascular Medicine

Pulmonary embolism (PE) is increasingly recognized as an episode of care that extends well beyond hospital discharge. Current guidance is distributed across several documents: the

OCT 16, 2026 · JOURNAL ARTICLE

Serial urinary NGAL and CK20 for dynamic cardiovascular risk stratification in non-muscle-invasive bladder cancer: a retrospective clinical cohort study

Frontiers in Cardiovascular Medicine

Background Non-muscle-invasive bladder cancer (NMIBC) is commonly managed with intravesical BCG, whereas pembrolizumab is reserved for selected BCG-unresponsive high-risk disease.

OCT 16, 2026 · JOURNAL ARTICLE

Time as an indispensable causal dimension in cardiovascular diseases: toward a four-dimensional biology

Frontiers in Cardiovascular Medicine

Heart failure (HF) exhibits distinctive event-and time-dependent patterns in incidence and progression dynamics. Over time, the heart first undergoes (mal)adaptive cellular, tissue

OCT 13, 2026 · JOURNAL ARTICLE

High-sensitivity troponin T as a predictor of cardiovascular events in colorectal cancer patients undergoing chemotherapy: results of the COLOVASC prospective cohort study

Frontiers in Cardiovascular Medicine

Background Fluoropyrimidine-based chemotherapy is associated with cardiovascular events in patients with colorectal cancer, yet validated tools for pre-treatment cardiovascular ris

OCT 13, 2026 · REVIEW

Factors associated with mortality in patients with atrial fibrillation: an umbrella review of systematic reviews and meta-analyses

Frontiers in Cardiovascular Medicine

Background This study synthesized published meta-analyses to assess the quality, bias, and strength of evidence regarding mortality risk factors in patients with atrial fibrillatio

OCT 9, 2026 · REVIEW

Efficacy of beta-blockers in preventing cardiotoxicity in breast cancer patients receiving anthracyclines: a GRADE-assessed systematic review and meta-analysis with trial sequential analysis

Frontiers in Cardiovascular Medicine

Purpose Anthracycline-induced cardiotoxicity remains an important complication in patients with breast cancer receiving systemic therapy, and effective preventive strategies remain

OCT 9, 2026 · JOURNAL ARTICLE

Baseline SII and SIRI identify immune-inflammatory susceptibility and improve risk stratification of early subclinical cardiac dysfunction during non-steroidal aromatase inhibitor therapy

Frontiers in Cardiovascular Medicine

Background Non-steroidal aromatase inhibitors (NSAIs) are a cornerstone of adjuvant endocrine therapy in postmenopausal women with hormone receptor-positive (HR+) breast cancer. Gi